Mpox (Monkeypox): Symptoms, Transmission, Treatment, and Prevention
What Is Mpox?
Mpox (formerly monkeypox) is a viral zoonosis caused by the monkeypox virus (Orthopoxvirus genus, related to smallpox). Two clades exist: Clade I (Central Africa, more severe) and Clade II (West Africa, responsible for the 2022 global outbreak).
Symptoms (Typically 5–21 Days Post-Exposure)
- Prodrome (0–5 days): Fever, headache, myalgia, backache, lymphadenopathy (distinguishes from smallpox), chills, exhaustion.
- Rash progression: Macules → papules → vesicles → pustules → scabs → heal. Often starts on face/oral mucosa and spreads centrifugally. The 2022 Clade IIb variant frequently presents with anogenital/perioral onset and fewer lesions.
- Duration: 2–4 weeks. Infectious until all scabs separate and fresh skin forms.
Transmission
- Close contact: Skin-to-skin (rash, scabs), respiratory droplets (prolonged face-to-face), mucosal contact (kissing, sex).
- Fomites: Contaminated bedding, towels, clothing, surfaces.
- Vertical: Pregnant person to fetus/newborn.
- Animal: Bite/scratch, bushmeat preparation (endemic regions).
Not airborne like measles or COVID-19.
Risk Groups (2022 Outbreak)
- GBMSM (gay, bisexual, and other men who have sex with men) – sexual networks drove spread.
- Sex workers, people with multiple partners.
- Immunocompromised individuals (HIV/CD4 <200 → severe disease).
- Pregnant women, children under 8.
Diagnosis
PCR on lesion swab (roof/fluid/scab). Orthopoxvirus positive → confirmatory MPXV PCR. Available at commercial labs and LRN.
Treatment
- Supportive: Pain control (topical lidocaine, oral analgesics), hydration, skin care (antiseptic washes), treat secondary bacterial infection.
- Antivirals (tecovirimat/TPOXX): FDA-approved for smallpox; expanded access (EA-IND) for mpox. Prioritized for severe/immunocompromised/ocular/mucosal involvement. Oral/IV formulations.
- VIGIV: Vaccinia immune globulin for severe immunodeficiency.
Prevention
- Vaccination: JYNNEOS (MVA-BN) – 2-dose series, 28 days apart. Pre-exposure (PrEP) for high-risk; post-exposure (PEP) ≤4 days (ideal) to 14 days. ACAM2000 (live replicating) – alternative, more side effects.
- Behavioral: Reduce partners, avoid skin-to-skin contact with symptomatic individuals, don't share linens/utensils.
- Hygiene: Handwashing, surface disinfection (EPA List Q).
- Isolation: Until all lesions healed.
Current Status
The 2022 global outbreak (Clade IIb) has been largely controlled in high-income countries through vaccination and behavior change. Endemic transmission persists in Central/West Africa. WHO maintains surveillance.
Viral Infections - Related Articles
- Foot-and-Mouth Disease (FMD): Symptoms, Prevention & Impact
- Cytomegalovirus (CMV) Infection: Manifestations by Population
- Why the Bubonic Plague Hasn't Returned as a Pandemic: Public Health Triumphs
- What Happens to Measles Virus Without a Host? Extinction Dynamics
- Hepatitis Virus Survival Outside the Body: A Type-by-Type Guide
- Viral Conjunctivitis (Pinkeye): Symptoms, Treatment & Relief
- West Nile Virus: Symptoms, Severity, and Prognosis
